Company news from the 10/17/06 News Brief

Share this article:
Boehringer Ingelheim said it would purchase the US marketing rights to heartburn drug Zantac for $509.5 million as part of Pfizer’s sale of its consumer unit to Johnson & Johnson. In a statement about the purchase, Boehringer Ingelheim Corp. president and CEO J. Martin Carroll said Zantac, an OTC drug, complements the firm’s existing nonprescription franchise, which includes laxative Dulcolax. Zantac will be distributed through the same retail channels as the Dulcolax business, which will allow for increased promotion and marketing efficiencies, Carroll said. Pfizer is selling Zantac to help facilitate FTC approval of the planned, $16.6 billion sale of its Consumer Healthcare business to J&J, a deal expected to close by year’s end. Boehringer Ingelheim GmbH is the world’s biggest closely held drugmaker.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.